Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The cytogenetics of myelodysplastic syndromes.

Literature DB >> 11640866

The cytogenetics of myelodysplastic syndromes.

Abstract

The myelodysplastic syndromes are a collection of five clinico-pathological entities with a wide spectrum of clinical behaviours and survival outcomes. Cytogenetic analysis has been instrumental in refining the prognosis, predicting the likelihood of progression to acute myeloid leukaemia and median survival, and in establishing clonality of these diseases. This review highlights the most frequent abnormalities and summarizes their clinical and genetic features. Copyright 2001 Harcourt Publishers Ltd.

Entities: Disease

Mesh：

Year: 2001 PMID： 11640866 DOI： 10.1053/beha.2001.0151

Source DB: PubMed Journal: Best Pract Res Clin Haematol ISSN： 1521-6926 Impact factor: 3.020

Keyword Cloud
Cited

13 in total

1. Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome.

Authors: Kelly A McGowan; Wendy W Pang; Rashmi Bhardwaj; Marcelina G Perez; John V Pluvinage; Bertil E Glader; Reem Malek; Susan M Mendrysa; Irving L Weissman; Christopher Y Park; Gregory S Barsh
Journal: Blood Date: 2011-07-25 Impact factor: 22.113

2. A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes.

Authors: Anair Graciela Lema Fernandez; Barbara Crescenzi; Valentina Pierini; Valeria Di Battista; Gianluca Barba; Fabrizia Pellanera; Danika Di Giacomo; Giovanni Roti; Rocco Piazza; Emmalee R Adelman; Maria E Figueroa; Cristina Mecucci
Journal: Leukemia Date: 2019-03-28 Impact factor: 11.528

Review 3. Myelodysplastic syndromes: an update on molecular pathology.

Authors: Mar Tormo; Isabel Marugán; Marisa Calabuig
Journal: Clin Transl Oncol Date: 2010-10 Impact factor: 3.405

4. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.

Authors: Chi Young Ok; Keyur P Patel; Guillermo Garcia-Manero; Mark J Routbort; Bin Fu; Guilin Tang; Maitrayee Goswami; Rajesh Singh; Rashmi Kanagal-Shamanna; Sherry A Pierce; Ken H Young; Hagop M Kantarjian; L Jeffrey Medeiros; Rajyalakshmi Luthra; Sa A Wang
Journal: Leuk Res Date: 2014-12-20 Impact factor: 3.156

5. Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.

Authors: Merav Bar; Derek Stirewalt; Era Pogosova-Agadjanyan; Vitas Wagner; Ted Gooley; Nissa Abbasi; Ravi Bhatia; H Joachim Deeg; Jerald Radich
Journal: Transl Oncogenomics Date: 2008-05-29

6. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Authors: Alfonso Quintás-Cardama; Naval Daver; Hawk Kim; Courtney Dinardo; Elias Jabbour; Tapan Kadia; Gautam Borthakur; Sherry Pierce; Jianqin Shan; Marylou Cardenas-Turanzas; Jorge Cortes; Farhad Ravandi; William Wierda; Zeev Estrov; Stefan Faderl; Yue Wei; Hagop Kantarjian; Guillermo Garcia-Manero
Journal: Clin Lymphoma Myeloma Leuk Date: 2014-05-06

The cytogenetics of myelodysplastic syndromes.

1. Reduced ribosomal protein gene dosage and p53 activation in low-risk myelodysplastic syndrome.

2. A distinct epigenetic program underlies the 1;7 translocation in myelodysplastic syndromes.

Review 3. Myelodysplastic syndromes: an update on molecular pathology.

4. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases.

5. Gene expression patterns in myelodyplasia underline the role of apoptosis and differentiation in disease initiation and progression.

6. A prognostic model of therapy-related myelodysplastic syndrome for predicting survival and transformation to acute myeloid leukemia.

Review 7. Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?

8. Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes.

9. The role of magnetic resonance imaging in the evaluation of transfusional iron overload in myelodysplastic syndromes.

Review 10. Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes.